The company may be in line for more COVID-19 grant money.
News & Analysis: Inovio Pharmaceuticals
Investors like the biotech's good news from a phase 2 clinical trial.
An old malaria drug may unseat newer investigational coronavirus treatments -- if data is confirmed.
The results from its study of VGX-3100 are an encouraging signal that the biotech's coronavirus vaccine might work too.
Inovio Pharmaceuticals Gets Help From Ology Bioservices and the Defense Department with Its COVID-19 Vaccine Candidate
A $11.9 million Defense Department grant will support the companies as they develop and test INO-4800.
These five biotech stocks could post life-changing gains for early-bird investors.
Both of these companies are in the thick of the hunt to develop a coronavirus vaccine. Which stock is the better pick right now?
Biotech stocks related to the coronavirus have surged -- but once the outbreak wanes, future gains will depend on the rest of their pipelines.
Investors might be coming to grips with the long odds facing the company.
The biotech company has trounced the recent market thanks to its work developing a coronavirus vaccine, but you still might want to stay away.